Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (CSE: INNO )

0.3350 +0.0050 (+1.52%)
Official Closing Price Updated: 3:37 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,500
Open 0.3250
Bid (Size) 0.3350 (5,000)
Ask (Size) 0.3400 (85,000)
Prev. Close 0.3300
Today's Range 0.3250 - 0.3350
52wk Range 0.1800 - 0.5200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis... 
Via Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, 
Via Benzinga

Performance

YTD
+39.58%
+39.58%
1 Month
-9.46%
-9.46%
3 Month
+34.00%
+34.00%
6 Month
+36.73%
+36.73%
1 Year
+13.56%
+13.56%

More News

Read More
Industry Update: Innocan Pharma Accelerates Commercialization in Europe Following Impressive Revenue Growth
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Innovative Delivery Systems Create Unique Opportunities in the Billion-Dollar Pain Market (CSE: INNO)
Via AB Newswire
Topics Cannabis
Exposures Cannabis
Innocan Pharma Provides an Operational Update
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
Via Newsfile
Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Via Newsfile
Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Via Newsfile
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence COVID-19 Supply Chain
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Via Newsfile
Topics Economy Supply Chain
Exposures COVID-19 Economy Supply Chain
Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Via Newsfile
Topics Intellectual Property Supply Chain
Exposures COVID-19 Intellectual Property Supply Chain
Innocan Pharma Engages Lytham Partners to Lead Investor Relations and Shareholder Communication Program
Via Newsfile
Topics Cannabis Supply Chain
Exposures COVID-19 Cannabis Supply Chain
Innocan Pharma Announces Trading on the OTCQB Venture Market and DTC Eligibility of Its Common Shares in the United States
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.